Director/PDMR Shareholding

Dechra Pharmaceuticals PLC

("the Company")

24 May 2012

Director / PDMR Shareholding

Dechra Pharmaceuticals PLC ("the Company") has been notified that on 23 May 2012 Ian Page, Chief Executive, transferred 2,000 shares in the Company to his son, Michael John Page, for nil consideration.

The total beneficial holding of Ian Page following this transaction is unchanged, being 859,751 shares, which represents 0.99% of current issued share capital.

 For further information

Zoe Goulding, Company Secretary

Telephone number: 01782 771100